4D Molecular Therapeutics Inc
NASDAQ:FDMT

Watchlist Manager
4D Molecular Therapeutics Inc Logo
4D Molecular Therapeutics Inc
NASDAQ:FDMT
Watchlist
Price: 10.95 USD 1.01%
Market Cap: 625.7m USD

Operating Margin
4D Molecular Therapeutics Inc

-191 982.5%
Current
-174 900.3%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-191 982.5%
=
Operating Profit
-230.4m
/
Revenue
120k

Operating Margin Across Competitors

No Stocks Found

4D Molecular Therapeutics Inc
Glance View

Market Cap
625.7m USD
Industry
Biotechnology

4D Molecular Therapeutics, Inc. engages in the design, development, and commercialization of transformative gene therapeutic products for serious unmet medical conditions. The company is headquartered in Emeryville, California and currently employs 124 full-time employees. The company went IPO on 2020-12-11. The firm is focused on creating and developing targeted and evolved adeno-associated viruses (AAV) vectors. The Company’s product candidates are focused various areas, including ophthalmology, cardiology, and pulmonology. The firm's product candidates include 4D-125, 4D-150, 4D-110, 4D-310, and 4D-710. 4D-125 for the treatment of patients with X-Linked Retinitis Pigmentosa (XLRP) with retinitis pigmentosa GTPase regulator (RPGR) gene. 4D-150 is developed for the treatment of wet age-related macular degeneration (wet-AMD). 4D-110 is developed for the treatment of choroideremia. 4D-310 is developed for the systemic treatment of Fabry disease. The firm is developing 4D-710 for the treatment of a broad range of patients with cystic fibrosis independent of their cystic fibrosis transmembrane conductance regulator (CFTR).

FDMT Intrinsic Value
4.07 USD
Overvaluation 63%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-191 982.5%
=
Operating Profit
-230.4m
/
Revenue
120k
What is the Operating Margin of 4D Molecular Therapeutics Inc?

Based on 4D Molecular Therapeutics Inc's most recent financial statements, the company has Operating Margin of -191 982.5%.

Back to Top